Ken Warrington
Director/Miembro de la Junta en BIOSTEM TECHNOLOGIES INC .
Perfil
Ken Warrington is currently the Director at BioStem Technologies, Inc. He previously worked as the Chief Technology Officer at Lacerta Therapeutics, Inc. from 2017 to 2019.
In 2020 to 2021, he was the Head-Strategy & Innovations at GENSCRIPT PROBIO USA INC.
Prior to that, from 2019 to 2020, he served as the Senior VP-Operations & Business Development at Biostem Life Sciences, Inc. Mr. Warrington holds a doctorate degree from the University of Florida, which he obtained in 2000.
He also has an undergraduate degree from The St. Lawrence College, which he received in 1993.
Cargos activos de Ken Warrington
| Empresas | Cargo | Inicio |
|---|---|---|
| BIOSTEM TECHNOLOGIES INC | Director/Miembro de la Junta | 01/03/2022 |
Antiguos cargos conocidos de Ken Warrington.
| Empresas | Cargo | Fin |
|---|---|---|
| GENSCRIPT PROBIO USA INC. | Corporate Officer/Principal | 01/12/2021 |
| Biostem Life Sciences, Inc. | Director de Operaciones | 01/05/2020 |
Lacerta Therapeutics, Inc.
 Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Director Técnico/Científico/I+D | 01/05/2019 |
Formación de Ken Warrington.
| University of Florida | Doctorate Degree |
| The St. Lawrence College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BIOSTEM TECHNOLOGIES INC | Health Technology |
| Empresas privadas | 3 |
|---|---|
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | Health Technology |
| GENSCRIPT PROBIO USA INC. | |
| Biostem Life Sciences, Inc. |
- Bolsa de valores
- Insiders
- Ken Warrington
